Director, Sarcoma Medical oncology
Rutgers Cancer Institute of New Jersey
I am excited to lead the Rutgers Cancer Institute of New Jersey sarcoma medical oncology group. I come by way of an undergraduate degree in molecular biology at UCLA and MD at Tulane school of medicine. I completed internal medicine residency at Yale-New Haven hospital and a hematology/oncology fellowship at MD Anderson Cancer Center. I see patients as part of the Melanoma and Sarcoma Program and the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute.
I belive every cancer and every patient is unique and there is no “usual” treatment. Treatment decisions are made using the latest in diagnostic techniques such as next-generation DNA sequencing which gives the particular genomic profile of a tumor. I use this data in my practice to design an individualized treatment plan for each of my patients implementing a variety of tools at my disposal including targeted therapy, chemotherapy, and immunotherapy to achieve the best possible results. I also ensure that the treatment plan fits with the patient’s lifestyle.
It is my goal to provide the latest and most advanced therapies for my patients, making sure that novel drugs are available as part of a clinical trial. I educate my patients on the importance of clinical trials and encourage them to participate not only for themselves, but for cancer patients worldwide – today and in the future. My particular interest is in drugs that target specific drivers of a tumor, a mission that is bolstered by my dual participation in the Rutgers precision medicine initiative and the phase I investigation therapeutics department. I am also honored to serve as a co-prinicple investigator for the TRACK (Target Rare Cancer Knowledge) study.
